April 18, 2018 09:53 AM IST
The market breadth was in favour of the advances with 900 stocks advancing while 658 declined and 471 remained unchanged. On the other hand, in the BSE, 988 stocks advanced and 705 declined and 89 remained unchanged.
April 17, 2018 02:06 PM IST
"The company is fairly valued at current market price. However, if Q4FY18 results are robust then we can expect a target of Rs 650 by FY19 end," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.
April 17, 2018 12:39 PM IST
"Its respiratory platform will be the key driver in scaling up its US business trajectory even as its India continues to grow at double-digits. We have a buy rating on the stock with a target of Rs 650," says S Ranganathan, Head of Research at LKP Securities.
April 16, 2018 09:05 PM IST
"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.
April 16, 2018 05:58 PM IST
Net Sales are expected to increase by 6.2 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 3,805.3 crore, according to Edelweiss.
April 16, 2018 03:04 PM IST
The top Nifty gainers included Cipla which was jumped 4 percent while Grasim Industries gained 2.5 percent. Hero MotoCorp and Indiabulls Housing Finance along with Kotak Mahindra Bank were the other gainers.
April 16, 2018 12:58 PM IST
The US Food and Drug Administration has recently completed its inspection of Cipla's Indore facility.
April 02, 2018 12:18 PM IST
The market breadth was in favour of the advances with 1432 stocks advancing while 306 declined and 314 remained unchanged. On the other hand, in the BSE, 1997 stocks advanced and 546 declined and 130 remained unchanged.
March 28, 2018 12:30 PM IST
Here are the biggest deals in the pharmaceuticals industry. Read on to find out which were successful.
March 20, 2018 08:48 PM IST
The United States Food and Drug Administration (USFDA) had conducted a product specific pre-approval inspection at company's Goa plant in January 2018, Cipla said in a BSE filing.
March 20, 2018 10:12 AM IST
Cipla told CNBC-TV18 the Goa unit observations are procedural & addressable in nature.
February 27, 2018 08:48 PM IST
Cipla has put its biosimilar development programme on the backburner as part of business rationalisation. However, the drug maker is trying to distribute products of other companies through in-licensing and partnerships.
February 21, 2018 03:52 PM IST
Geojit recommended hold rating on Cipla with a target price of Rs 653 in its research report dated February 21, 2018.
February 12, 2018 09:23 AM IST
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Bata India, Cipla, Hindustan Unilever and Tata Elxsi and can sell Bharti Airtel.
February 08, 2018 04:49 PM IST
KR Choksey is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 714 in its research report dated February 08, 2018.
February 08, 2018 11:12 AM IST
Rajat Bose of rajatkbose.com recommends buying Gujarat Alkalies, GNFC and Cipla.
February 08, 2018 10:51 AM IST
CLSA estimates robust 30 percent earnings CAGR for FY18-20, while retaining Buy rating on the stock with a target price of Rs 750 per share.
February 08, 2018 09:48 AM IST
The market breadth was in favour of the advances on Thursday morning with 1338 stocks advancing while 241 stocks declined and 427 stocks remained unchanged. On the BSE, 1548 stocks advanced while 349 stocks declined and 52 remained unchanged.
February 07, 2018 02:12 PM IST
Operating profit at Rs 818.7 crore and margin at 20.9 percent were ahead of estimates of Rs 791 crore and 19.3 percent, respectively.
February 07, 2018 12:48 PM IST
Operating profit is expected to increase 16.7 percent year-on-year to Rs 791 crore and margin may expand 70 basis points to 19.3 percent in Q3.
January 29, 2018 11:45 AM IST
Cipla in a BSE filing said it has received final approval from the United States Food and Drug Administration (USFDA) for tenofovir disoproxil fumarate tablets, 300 mg.
January 25, 2018 11:28 AM IST
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Cipla, IndusInd Bank, Maruti Suzuki and Apollo Tyres and can sell India Cements.
January 25, 2018 10:04 AM IST
The market breadth was in favour of the advances on Thursday morning with 804 stocks advancing as against 782 declines while 418 remained unchanged. On the other hand, 1051 stocks advanced and 948 stocks declined while 85 remained unchanged on the BSE.
January 23, 2018 01:47 PM IST
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Cipla, DLF, Sun TV Network and ITC and exit Apex Frozen Foods.
January 23, 2018 11:38 AM IST
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Ashok Leyland, NMDC and JSW Steel.
